PBYIPUMA BIOTECHNOLOGY, INC.
- Analyst Upgrades
TD Cowen Maintains Hold on Puma Biotechnology, Raises Price Target to $6
TD Cowen analyst Marc Frahm maintains Puma Biotechnology with a Hold and raises the price target from $5 to $6. ...
- BusinessWire
Puma Biotechnology Reports Second Quarter 2026 Financial Results
Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June ...
- BusinessWire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on August 3, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit ...
- BusinessWire
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, August 6, 2026, following the release of its second quarter 2026 financial ...
- BusinessWire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on July 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards ...
- BusinessWire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on June 1, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards ...
- BusinessWire
Puma Biotechnology Reports First Quarter 2026 Financial Results
Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, ...
- BusinessWire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on May 5, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards ...
- BusinessWire
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May 7, 2026, following the release of its first quarter 2026 financial ...
- BusinessWire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on April 1, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards ...
- CNBC
Sportswear giant Adidas drops 8% after profit guidance disappoints
Adidas shares have fallen about 43% over the past year as investors remain skeptical about the growth prospects of the global sportswear industry. ...
- BusinessWire
Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are for the fourth ...
- BusinessWire
Puma Biotechnology to Present at TD Cowen's 46th Annual Health Care Conference
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:30 p.m. ET on Monday, ...
- BusinessWire
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, February 26, 2026, following the release of its fourth quarter and full year ...
- BusinessWire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on February 3, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit ...
- BusinessWire
Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ:NBI), effective at the close of trading on Friday, December 19, ...
- BusinessWire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on December 1, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit ...
- BusinessWire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on November 5, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit ...
- BusinessWire
Puma Biotechnology Reports Third Quarter 2025 Financial Results
Raising 2025 NERLYNX® revenue and net income estimates Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2025. Unless ...
- BusinessWire
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, Nov. 6, 2025, following the release of its third quarter 2025 financial ...
- BusinessWire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on October 1, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit ...
- BusinessWire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on September 2, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit ...
- BusinessWire
Puma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 1:00 ...
- BusinessWire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on August 5, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit ...
- Earnings Call Transcripts
Puma Biotechnology, Inc. (PBYI) Q2 2025 Earnings Call Transcript
Puma Biotechnology, Inc. (PBYI) Q2 2025 Earnings Call Transcript ...